Status:
COMPLETED
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-6231 in Healthy Adults
Lead Sponsor:
ModernaTX, Inc.
Conditions:
Healthy Volunteers
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
There are 2 parts to this study: a single ascending dose (single dose of mRNA-6231) part and a multiple ascending dose (repeat doses of mRNA-6231) part. The main goal of this study is to evaluate the ...
Eligibility Criteria
Inclusion
- Key
- Understand and agree to comply with the study procedures and provide written informed consent
- Key
Exclusion
- Has received any investigational product (for example, study drug, biologic, device) within 30 days or 5 elimination half-lives, whichever is longer
- Pregnant or lactating women
- Men and women of childbearing potential without effective contraception during the study
- Has any lab abnormalities or clinically significant medical condition that could interfere with the interpretation of study results or limit the participant's enrollment
Key Trial Info
Start Date :
July 28 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 2 2022
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT04916431
Start Date
July 28 2021
End Date
August 2 2022
Last Update
August 10 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Nucleus Network Limited
Melbourne, Victoria, Australia, 3004